Compare Crispr Therapeutics AG (CRSP) vs Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF (PDBC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF — how do they compare? Crispr Therapeutics AG trades at $53.15 (market cap $4.88B), while Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF trades at $19.74 (market cap $7.77B). The key difference: Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF is the larger of the two by market cap, and Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF is trading nearer its 52-week high, Crispr Therapeutics AG nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Crispr Therapeutics AG for 77 Days and Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF for 56 Days on average.
| CRSP | PDBC | |
|---|---|---|
Market Cap | $4.88B | $7.77B |
Volume | 2,861,747 | 6,100,303 |
Sector | Health | — |
52-Week High | $74.92 | $20.10 |
52-Week Low | $44.34 | $13.16 |
Typical Hold Time | 77 Days | 56 Days |
Enterprise Value | $3.30B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $52.35, down 3.06% with bearish technical signals. The company shows negative profitability metrics including -$581.6M net income and -4,101.26% net margin for 2025, though revenue is expected to grow from $0 to $11M in 2026. Recent news highlights upcoming clinical data presentations and CASGEVY's commercial potential, with analyst consensus leaning bullish despite fundamental challenges.
The outlook remains speculative with significant cash burn but promising pipeline catalysts. Investment opportunity lies in gene-editing breakthroughs and CASGEVY adoption, while risks include sustained losses, clinical trial outcomes, and competitive pressure. Wall Street maintains a $67.83 price target, suggesting 30% upside if execution improves.
PDBC, the Invesco Optimum Yield Diversified Commodity Strategy ETF, trades at $19.66, up 1.29% with strong bullish momentum from moving averages. The ETF has delivered exceptional performance with 45.66% year-to-date gains through Q3 2026, driven by energy and agricultural commodity strength amid geopolitical tensions. Recent institutional activity shows significant position increases despite a 215% surge in short interest in September.
The outlook remains positive given strong commodity trends and defensive positioning benefits, though elevated short interest and RSI levels near overbought territory suggest potential near-term volatility. Commodity exposure provides inflation hedging advantages but remains sensitive to geopolitical developments and global economic conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF
The fund is an actively managed exchange-traded fund ("ETF") that seeks to achieve its investment objective by investing in a combination of financial instruments that are economically linked to the world's most heavily traded commodities. Commodities are assets that have tangible properties, such as oil, agricultural produce or raw metals.
Read more on PDBC →
